MARLBOROUGH, Mass.--(BUSINESS WIRE)--EXACT Sciences Corporation (NASDAQ: EXAS) today announced that a major gastroenterology journal has accepted for publication a multi-center, prospective study of EXACT’s Version 2 technology for early colorectal cancer detection using stool-based DNA testing.
